Alan W. Tamarelli

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Cooley advised Archon Biosciences, a biotechnology company pioneering computationally designed antibody cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, on its $20 million seed financing led by Madrona Ventures.

Cooley advised AviadoBio, a company focused on gene therapy for neurodegenerative disorders, on its exclusive option and license agreement with Astellas Pharma for AVB-101, an investigational, adeno-associated virus (AAV)-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (FTD-GRN).

Cooley advised Ionis Pharmaceuticals (Nasdaq: IONS), a biotechnology research company inventing medicines that bring better futures to people with serious diseases, on its $500.3 million underwritten public offering of common stock.